MMF and eye disease
Immunosuppressive treatment has shown to be effective in various ocular inflammatory disorders. Factors limiting their use are the individual response and the rate of side effects. This report summarizes our knowledge about the use of mycophenolate mofetil (MMF) in the treatment of ocular cicatricia...
Gespeichert in:
| Veröffentlicht in: | Lupus 2005-03, Vol.14 (3_suppl), p.50-54 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | 3_suppl |
| container_start_page | 50 |
| container_title | Lupus |
| container_volume | 14 |
| creator | Zierhut, M Stübiger, N Siepmann, K Deuter, CME |
| description | Immunosuppressive treatment has shown to be effective in various ocular inflammatory disorders. Factors limiting their use are the individual response and the rate of side effects. This report summarizes our knowledge about the use of mycophenolate mofetil (MMF) in the treatment of ocular cicatricial pemphigoid (OCP), uveitis, atopic keratoconjunctivitis (AKC), prevention of graft rejection after penetrating keratoplasty (PK) and scleritis. Controlled studies have been performed for prevention of graft rejection after PK, showing MMF as effective in the prevention of graft rejection as cyclosporine A. In experimental uveitis, MMF has been demonstrated to be highly effective in prevention of retinal destruction. A number of studies have now shown that MMF also seems effective in uveitis. There are also studies with smaller patient groups which point out the effectiveness of MMF in OCP, AKC, and scleritis. In most of the studies, the spectrum of side effects was small, compared to other immunosuppressives. |
| doi_str_mv | 10.1191/0961203305LU2119OA |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17807998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_0961203305LU2119OA</sage_id><sourcerecordid>17807998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-f7a4f2d582841f264b75aa417bcf28a3d149a31f72413468bcb5225c1e89231f3</originalsourceid><addsrcrecordid>eNp9kM1Lw0AUxBdRsFZP3jwFD95i9739PpZiVWjpxZ6XTbIrLWlSs82h_71bIhQUPD2Y95thGEIegD4DGJhQIwEpY1Qs1piU1fSCjIArlacPXpLRCchPxDW5iXFLKWVg5IjcL5fzzDVV5o8-qzbRu-hvyVVwdfR3P3dM1vOXj9lbvli9vs-mi7xkXBzyoBwPWAmNmkNAyQslnOOgijKgdqwCbhyDoJAD41IXZSEQRQleG0w6G5OnIXfftV-9jwe728TS17VrfNtHC0pTZYxO4OMvcNv2XZO6WUSUUgqEBOEAlV0bY-eD3XebneuOFqg9jWT_jpRMk8EU3ac_p_7j-AZSSWN9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222666521</pqid></control><display><type>article</type><title>MMF and eye disease</title><source>SAGE Complete A-Z List</source><creator>Zierhut, M ; Stübiger, N ; Siepmann, K ; Deuter, CME</creator><creatorcontrib>Zierhut, M ; Stübiger, N ; Siepmann, K ; Deuter, CME</creatorcontrib><description>Immunosuppressive treatment has shown to be effective in various ocular inflammatory disorders. Factors limiting their use are the individual response and the rate of side effects. This report summarizes our knowledge about the use of mycophenolate mofetil (MMF) in the treatment of ocular cicatricial pemphigoid (OCP), uveitis, atopic keratoconjunctivitis (AKC), prevention of graft rejection after penetrating keratoplasty (PK) and scleritis. Controlled studies have been performed for prevention of graft rejection after PK, showing MMF as effective in the prevention of graft rejection as cyclosporine A. In experimental uveitis, MMF has been demonstrated to be highly effective in prevention of retinal destruction. A number of studies have now shown that MMF also seems effective in uveitis. There are also studies with smaller patient groups which point out the effectiveness of MMF in OCP, AKC, and scleritis. In most of the studies, the spectrum of side effects was small, compared to other immunosuppressives.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1191/0961203305LU2119OA</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>Lupus, 2005-03, Vol.14 (3_suppl), p.50-54</ispartof><rights>2005 Edward Arnold (Publishers) Ltd</rights><rights>2005 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-f7a4f2d582841f264b75aa417bcf28a3d149a31f72413468bcb5225c1e89231f3</citedby><cites>FETCH-LOGICAL-c345t-f7a4f2d582841f264b75aa417bcf28a3d149a31f72413468bcb5225c1e89231f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/0961203305LU2119OA$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/0961203305LU2119OA$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids></links><search><creatorcontrib>Zierhut, M</creatorcontrib><creatorcontrib>Stübiger, N</creatorcontrib><creatorcontrib>Siepmann, K</creatorcontrib><creatorcontrib>Deuter, CME</creatorcontrib><title>MMF and eye disease</title><title>Lupus</title><description>Immunosuppressive treatment has shown to be effective in various ocular inflammatory disorders. Factors limiting their use are the individual response and the rate of side effects. This report summarizes our knowledge about the use of mycophenolate mofetil (MMF) in the treatment of ocular cicatricial pemphigoid (OCP), uveitis, atopic keratoconjunctivitis (AKC), prevention of graft rejection after penetrating keratoplasty (PK) and scleritis. Controlled studies have been performed for prevention of graft rejection after PK, showing MMF as effective in the prevention of graft rejection as cyclosporine A. In experimental uveitis, MMF has been demonstrated to be highly effective in prevention of retinal destruction. A number of studies have now shown that MMF also seems effective in uveitis. There are also studies with smaller patient groups which point out the effectiveness of MMF in OCP, AKC, and scleritis. In most of the studies, the spectrum of side effects was small, compared to other immunosuppressives.</description><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kM1Lw0AUxBdRsFZP3jwFD95i9739PpZiVWjpxZ6XTbIrLWlSs82h_71bIhQUPD2Y95thGEIegD4DGJhQIwEpY1Qs1piU1fSCjIArlacPXpLRCchPxDW5iXFLKWVg5IjcL5fzzDVV5o8-qzbRu-hvyVVwdfR3P3dM1vOXj9lbvli9vs-mi7xkXBzyoBwPWAmNmkNAyQslnOOgijKgdqwCbhyDoJAD41IXZSEQRQleG0w6G5OnIXfftV-9jwe728TS17VrfNtHC0pTZYxO4OMvcNv2XZO6WUSUUgqEBOEAlV0bY-eD3XebneuOFqg9jWT_jpRMk8EU3ac_p_7j-AZSSWN9</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Zierhut, M</creator><creator>Stübiger, N</creator><creator>Siepmann, K</creator><creator>Deuter, CME</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200503</creationdate><title>MMF and eye disease</title><author>Zierhut, M ; Stübiger, N ; Siepmann, K ; Deuter, CME</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-f7a4f2d582841f264b75aa417bcf28a3d149a31f72413468bcb5225c1e89231f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zierhut, M</creatorcontrib><creatorcontrib>Stübiger, N</creatorcontrib><creatorcontrib>Siepmann, K</creatorcontrib><creatorcontrib>Deuter, CME</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zierhut, M</au><au>Stübiger, N</au><au>Siepmann, K</au><au>Deuter, CME</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MMF and eye disease</atitle><jtitle>Lupus</jtitle><date>2005-03</date><risdate>2005</risdate><volume>14</volume><issue>3_suppl</issue><spage>50</spage><epage>54</epage><pages>50-54</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Immunosuppressive treatment has shown to be effective in various ocular inflammatory disorders. Factors limiting their use are the individual response and the rate of side effects. This report summarizes our knowledge about the use of mycophenolate mofetil (MMF) in the treatment of ocular cicatricial pemphigoid (OCP), uveitis, atopic keratoconjunctivitis (AKC), prevention of graft rejection after penetrating keratoplasty (PK) and scleritis. Controlled studies have been performed for prevention of graft rejection after PK, showing MMF as effective in the prevention of graft rejection as cyclosporine A. In experimental uveitis, MMF has been demonstrated to be highly effective in prevention of retinal destruction. A number of studies have now shown that MMF also seems effective in uveitis. There are also studies with smaller patient groups which point out the effectiveness of MMF in OCP, AKC, and scleritis. In most of the studies, the spectrum of side effects was small, compared to other immunosuppressives.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1191/0961203305LU2119OA</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2005-03, Vol.14 (3_suppl), p.50-54 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17807998 |
| source | SAGE Complete A-Z List |
| title | MMF and eye disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A28%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MMF%20and%20eye%20disease&rft.jtitle=Lupus&rft.au=Zierhut,%20M&rft.date=2005-03&rft.volume=14&rft.issue=3_suppl&rft.spage=50&rft.epage=54&rft.pages=50-54&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1191/0961203305LU2119OA&rft_dat=%3Cproquest_cross%3E17807998%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222666521&rft_id=info:pmid/&rft_sage_id=10.1191_0961203305LU2119OA&rfr_iscdi=true |